As previously reported, Canaccord initiated coverage of Grail (GRAL) with a Buy rating and $32 price target The company offers the Galleri multi-cancer early detection test based on Grail’s proprietary targeted methylation platform and after having surveyed 20 clinicians and 253 potential patients to understand current reception for MCED, the analyst is “enthusiastic” about the long-term potential of MCED and Galleri, but sees “many steps GRAIL must clear along the way.” The firm believes the stock offers “solid upside from current levels” after reviewing Grail’s cash burn outlook and catalyst path, the analyst added.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRAL:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue